V. Daneluzzi, Hôpital Max Fourestier?Nan- terrre)

D. Zucman, Hôpital Foch?Suresnes); Gilles Force (Hôpital du Notre Dame du Perpétuel Secours?Levallois Perret)

T. Iram-la, CH de l'agglomération Mon- targeoise?Amilly?Montargis)

D. Bettinger-(-besançon-)-;-p, T. Barin, and T. Le, ); E Lagier (Aix-en-provence); A Vabret (Caen)

J. Plantier and (. C. Nicolle, Rouen); A Signoris-Schmuck (Grenoble)

B. Martha and . Goux, Chalon-sur-soane); AS Poirier (LaRoche-Sur-Yon)

L. Bocket, Lille); B Chanzy (Pringy); E Schvoerer (Nancy); S Fafi-Kremer (Stras- bourg)

C. Alba-sauviat, Chaumont); N Azencott (Dignes-les-bains) Data management and statistical analysis: A Besseghir

B. Gc, C. Fd, . Sm, and . Fb, Author Contributions Conceived and designed the experiments: BV CC GC. Performed the experiments: GC MB Analyzed the data: Contributed reagents/materials

R. 1. Poveda, E. Briz, V. Soriano, and V. , Enfuvirtide, the first fusion inhibitor to treat HIV infection, AIDS Rev, vol.7, pp.139-147, 2005.

J. Ren, L. Bird, P. Chamberlain, S. , G. Stuart et al., Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors, Proceedings of the National Academy of Sciences, vol.99, issue.22, pp.14410-14415, 2002.
DOI : 10.1073/pnas.222366699

D. Desbois, B. Roquebert, G. Peytavin, F. Damond, C. G. Bénard et al., In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors, Antimicrobial Agents and Chemotherapy, vol.52, issue.4, pp.1545-1548, 2008.
DOI : 10.1128/AAC.01284-07

URL : https://hal.archives-ouvertes.fr/inserm-00263591

B. Visseaux, C. Charpentier, M. Hurtado-nedelec, A. Storto, R. Antoine et al., In Vitro Phenotypic Susceptibility of HIV-2 Clinical Isolates to CCR5 Inhibitors, Antimicrobial Agents and Chemotherapy, vol.56, issue.1, pp.137-139, 2012.
DOI : 10.1128/AAC.05313-11

M. Espírito-santo, Q. Santos-costa, M. Calado, P. Dorr, A. Pereira et al., Susceptibility of HIV Type 2 Primary Isolates to CCR5 and CXCR4 Monoclonal Antibodies, Ligands, and Small Molecule Inhibitors, AIDS Research and Human Retroviruses, vol.doi, pp.10-10890124, 2011.
DOI : 10.1089/aid.2011.0124

P. Borrego, R. Calado, J. Marcelino, I. Bártolo, C. Rocha et al., Baseline susceptibility of primary HIV-2 to entry inhibitors, Antiviral Therapy, vol.17, issue.3, pp.565-570, 2012.
DOI : 10.3851/IMP1996

D. Armstrong-james, J. Stebbing, A. Scourfield, E. Smit, B. Ferns et al., Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc, Antiviral Research, vol.86, issue.2, pp.224-226, 2010.
DOI : 10.1016/j.antiviral.2010.02.324

S. Stegmann, M. Manea, C. Charpentier, F. Damond, M. Karmochkine et al., Foscarnet as salvage therapy in HIV-2-infected patient with antiretroviral treatment failure, Journal of Clinical Virology, vol.47, issue.1, pp.79-81, 2010.
DOI : 10.1016/j.jcv.2009.11.008

U. Caixas, J. Ferreira, A. Marinho, I. Faustino, N. Grilo et al., Long-term maraviroc use as salvage therapy in HIV-2 infection, Journal of Antimicrobial Chemotherapy, vol.67, issue.10, pp.2538-2539, 2012.
DOI : 10.1093/jac/dks240

URL : http://jac.oxfordjournals.org/cgi/content/short/67/10/2538

M. Calado, P. Matoso, Q. Santos-costa, M. Espirito-santo, J. Machado et al., Coreceptor usage by HIV-1 and HIV-2 primary isolates: The relevance of CCR8 chemokine receptor as an alternative coreceptor, Virology, vol.408, issue.2, pp.174-182, 2010.
DOI : 10.1016/j.virol.2010.09.020

A. Mörner, A. Björndal, J. Albert, V. Kewalramani, D. Littman et al., Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage, J Virol, vol.73, pp.2343-2349, 1999.

H. Blaak, P. Boers, R. Gruters, H. Schuitemaker, M. Van-der-ende et al., CCR5, GPR15, and CXCR6 Are Major Coreceptors of Human Immunodeficiency Virus Type 2 Variants Isolated from Individuals with and without Plasma Viremia, Journal of Virology, vol.79, issue.3, p.15650194, 2005.
DOI : 10.1128/JVI.79.3.1686-1700.2005

A. Mcknight, M. Dittmar, J. Moniz-periera, K. Ariyoshi, J. Reeves et al., A broad range of chemokine receptors are used by primary isolates of human immunodeficiency virus type 2 as coreceptors with CD4, J Virol, vol.72, pp.4065-4071, 1998.

A. Mörner, A. Björndal, A. Leandersson, A. J. Björling, E. Jansson et al., CCR5 or CXCR4 Is Required for Efficient Infection of Peripheral Blood Mononuclear Cells by Promiscuous Human Immunodeficiency Virus Type 2 Primary Isolates, AIDS Research and Human Retroviruses, vol.18, issue.3, pp.193-200, 2002.
DOI : 10.1089/08892220252781248

Y. Zhang, B. Lou, R. Lal, A. Gettie, P. Marx et al., Use of Inhibitors To Evaluate Coreceptor Usage by Simian and Simian/Human Immunodeficiency Viruses and Human Immunodeficiency Virus Type 2 in Primary Cells, Journal of Virology, vol.74, issue.15, pp.6893-6910, 2000.
DOI : 10.1128/JVI.74.15.6893-6910.2000

J. Lalezari, J. Gathe, C. Brinson, M. Thompson, C. Cohen et al., Safety, Efficacy, and Pharmacokinetics of TBR-652, a CCR5/CCR2 Antagonist, in HIV-1???Infected, Treatment-Experienced, CCR5 Antagonist???Naive Subjects, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.57, issue.2, pp.118-125, 2011.
DOI : 10.1097/QAI.0b013e318213c2c0

J. Gathe, J. Cade, E. Dejesus, J. Feinberg, J. Lalezari et al., Week 24 Primary Analysis of Cenicriviroc vs Efavirenz, in Combination with FTC/TDF, in Treatment-naïve HIV-1 Infected Adults with CCR5-tropic Virus, 20th Conference on Retroviruses and Opportunistic Infections (CROI), 2013.